Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2000

View Archived Issues

Large study will evaluate PTH-bisphosphonate combination therapy in osteoporosis

Fujisawa updates product pipeline

Paladin awarded Canadian distribution rights for testosterone transdermal patch

FDA issues approvable letter for diagnostic secretin

Vion initiates phase I trial of Triapine by continuous infusion

SciClone's Zadaxin now available in Italy

Company Profile: ChemoCentryx

Z-338 tested in isolated opossum LES

Rofecoxib associated with reduced risk of GI adverse effects

Phase I/II data reported for Millennium's humanized alpha4beta7 antibody

Enzo Biochem's tolerance induction therapy may be useful in GVHD

Azimilide and dofetilide highlighted at NASPE

Ophidian suspends research and product development activities

Losartan metabolite EXP-3174 does not possess antiarrhythmic properties

Centaur announces phase IIa stroke trial results

Triangle updates Coviracil development progress

BioNumerik's anticancer products show promise in early clinical trials

IMC-1C11 exhibits antiangiogenic activity and excellent safety in animal models

Phase I clinical trials assess different schedules of CCI-779, a new signal transduction inhibitor

PEG-Intron monotherapy approved for HCV in E.U.

Immunosuppressive and antitumor properties of new histone deacetylase inhibitor WF-27082B

SB continues research aimed at discovering new chemokine receptor antagonists

Selective human NK3 receptor antagonists designed at Sanofi-Synthelabo

New activators of soluble guanylate cyclase especially useful for cardiovascular disorders

Ortho-McNeil describes cyclopropanes with utility in calcium imbalance and metabolism disorders

Australian researchers discover novel conotoxin peptides that inhibit neuronal amine transporters

New member of the follistatin family identified by ZymoGenetics

FDA approves Relenza for treatment of pediatric influenza; E.U. prophylaxis filing updated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...